761 Stock Overview
A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 761 from our risk checks.
Pharmanutra S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €53.50 |
| 52 Week High | €63.10 |
| 52 Week Low | €45.00 |
| Beta | 0.34 |
| 11 Month Change | -3.08% |
| 3 Month Change | 4.49% |
| 1 Year Change | 6.36% |
| 33 Year Change | -27.90% |
| 5 Year Change | n/a |
| Change since IPO | 44.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 761 | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | -3.4% | -0.8% | -1.3% |
| 1Y | 6.4% | -7.6% | 7.4% |
Return vs Industry: 761 exceeded the German Personal Products industry which returned -7.6% over the past year.
Return vs Market: 761 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 761 volatility | |
|---|---|
| 761 Average Weekly Movement | 4.8% |
| Personal Products Industry Average Movement | 3.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 761 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 761's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 112 | Roberto Lacorte | www.pharmanutra.it |
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company’s products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, Cetilar Nutrition, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2.
Pharmanutra S.p.A. Fundamentals Summary
| 761 fundamental statistics | |
|---|---|
| Market cap | €516.91m |
| Earnings (TTM) | €16.27m |
| Revenue (TTM) | €113.67m |
31.8x
P/E Ratio4.5x
P/S RatioIs 761 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 761 income statement (TTM) | |
|---|---|
| Revenue | €113.67m |
| Cost of Revenue | €68.61m |
| Gross Profit | €45.06m |
| Other Expenses | €28.79m |
| Earnings | €16.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.69 |
| Gross Margin | 39.64% |
| Net Profit Margin | 14.31% |
| Debt/Equity Ratio | 41.6% |
How did 761 perform over the long term?
See historical performance and comparison